449 related articles for article (PubMed ID: 22262486)
1. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
3. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
5. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
Shord SS; Cuellar S
J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
[TBL] [Abstract][Full Text] [Related]
10. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
Shord SS; Hamilton JM; Cuellar S
J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
12. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
[TBL] [Abstract][Full Text] [Related]
13. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients.
Steinmetz T; Kuhr K; Totzke U; Hellmich M; Heinz M; Neise M; Mittermüller J; Tessen HW; Reiser M; Severin K; Schmitz S
Clin Chem Lab Med; 2013 Sep; 51(9):1849-57. PubMed ID: 23729581
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
16. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
[TBL] [Abstract][Full Text] [Related]
17. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
Steensma DP; Sloan JA; Dakhil SR; Dalton R; Kahanic SP; Prager DJ; Stella PJ; Rowland KM; Novotny PJ; Loprinzi CL
J Clin Oncol; 2011 Jan; 29(1):97-105. PubMed ID: 21098317
[TBL] [Abstract][Full Text] [Related]
18. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
Mhaskar R; Djulbegovic B
JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
20. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
